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A. Summary 
Background: Randomized controlled trials (RCTs) are the best tool to evaluate the 
effectiveness of new oral anticoagulants (NOACs) in the prevention of thromboembolic 
events in patients with atrial fibrillation (AF). Inadequate reporting of RCTs is associated 
with biased estimates of treatment effects. 
 
Objective: To assess the overall reporting quality of RCTs, exploring the efficacy and 
safety of NOACs vs warfarin in patients with AF, based on the CONSORT statement. 
 
Methods: Pubmed was searched for English-language RCTs, comparing NOACs with 
warfarin in AF patients. RCTs were assessed overall and according to study type, NOAC 
and impact factor (IF) by means of the 25-item CONSORT checklist 2010. Statistical 
analysis was performed using chi-square test. 
Results: Search identified 92 references eligible for evaluation. Only 26% of studies 
reported >70% of Consort items. The type of analysis and NOAC, but not IF, were 
associated with the extent of compliance with Consort items(p<0,001). 100% of RCTs’ 
primary reports answered >70% of Consort items. 14 out of 38 overall items were 
reported by less than 50% of studies. 
Conclusion: Quality of reporting in RCTs’ primary reports is satisfactory enough. 
However, the overall compliance of studies is considered inadequate. Further 
improvement of reporting is necessary to assess the validity of clinical research. 
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B. Introduction 
Over the years, publication of medical research results and reporting of biomedical 
information has been strongly associated with the improvement of clinical trials, in 
terms of methodological approach, which led to the extraction of more robust results.1-
3 Randomized controlled trials, when properly designed, conducted and reported, are 
considered  a gold standard in clinical medicine and public health, for the evaluation of  
efficacy and effectiveness of new therapeutic or preventive interventions, as they 
minimize bias and provide the basis for valid statistical analysis.3-4  Consequently, RCTs 
have great potential to improve the quality of health care and control costs through 
careful comparison of alternative treatments.5-6 However, they can also lead to biased 
results and misleading information if they lack methodological rigor.3,7 Moreover, the 
wealth of biomedical information provided in numerous scientific journals, over the last 
decades, have raised additional problems such as publication bias, selection bias and 
retraction of invalid literature.1,8-9  
 
Nowadays, clinicians depend at a great extent, on the reporting of methodological 
approaches of published RCTs, in order to determine the validity and reliability of all 
information provided. Conclusions extracted, affect decision making, from patients’ 
management to the formulation of  treatment guidelines and national public health 
policies.10-11  So, readers of a trial report need lucid and complete information on its 
methodology and findings, in order to assess the strengths and limitations of a study 
more accurately.12-13 Unfortunately, attempted efforts frequently fail, because many 
reports omit critical methodological details.3,14-16  For example, only 45% of trial reports 
indexed in PubMed in 2000 and 56% in 2006 defined primary end point, and only 27% 
in 2000 and 45% in 2006 reported a sample size calculation.14-17 
 
As we can assume, the assessment of methodological quality of a trial is closely 
intertwined with the quality of reporting; that is, the extent to which a report provides 
information about the design, conduct, and analysis of the trial.7  
The quality of reporting should not be considered that necessarily depicts the quality of 
research. However, inadequate reporting often reflects faulty methods and a well-
conducted but badly reported trial could be misclassified7,13. Furthermore, faulty 
reporting makes the interpretation of results complex and leads to biased conclusions.18 
According to previous studies, randomized controlled trials, with a low reporting quality, 
tend to overestimate the effect of the evaluated intervention.19-21 
Thus, authors must provide transparent and thorough information about RCTs, in order 
to enable readers to estimate unbiased the treatment effects.10 
 
In response to misleading evaluation of poorly reported RCTs and its consequences, an 
international group of scientists and journal editors developed the CONSORT 
(Consolidated Standards of Reporting Trials) Statement to improve the quality of 
reporting of RCTs. It was first published in 1996 and updated in 2001 and 20103,10,22. The 
CONSORT statement comprises a checklist of essential items that should be included in 
reports of RCTs and a diagram for documenting the flow of participants through a trial. 
It is aimed at primary reports of RCTs with two group, parallel design. Most of CONSORT 
is also relevant to a wider class of trial designs, such as non-inferiority, equivalence, 
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factorial, cluster, and crossover trials3,22.  A CONSORT explanation and elaboration 
article was published in 2001, with the 2001 version of the CONSORT statement to help 
investigators and others to write or appraise trial reports23.  
 
Since CONSORT is an ongoing initiative, an expert meeting was held in Canada, in 
January 2007, to further revise the Consort 2001 Statement and its explanation and 
elaboration document and was eventually published as the CONSORT 2010 Statement3. 
This update includes a revised 25-item checklist, the flow diagram (not revised) and is 
accompanied by the revised CONSORT 2010 explanation and elaboration document. The 
2010 CONSORT Statement improves the wording and clarity of the previous checklist 
and incorporates recommendations related to topics that have only recently received 
recognition, such as selective outcome reporting bias24. Since its original publication in 
199610, CONSORT documents have been translated into 13 languages, and CONSORT 
statement has an Internet presence (http://www.consort–statement.org) to facilitate 
awareness and dissemination.3 
 
The CONSORT statement has a great impact on the scientific community worldwide, 
since it has been endorsed by numerous leading medical journals and major 
international editorial groups, such as the International Committee of Medical Journal 
Editors, the Council of Science Editors, and the World Association of Medical Editors.3,24 
To date, more than 600 biomedical journals worldwide have adopted the CONSORT 
Statement. It is the most well-known reporting guideline25. 
 
The aim of the CONSORT statement is to improve the quality of reporting of RCTs and 
to enable a critical assessment and reliable interpretation of trial methods and results. 
The Consort Statement is not meant to be a quality judgement tool and should not be 
used to this direction but rather as an evidence based guide for proper reporting of 
RCTs.3,24  
 
A number of review articles have assessed the quality of reporting of RCTs in several 
subspecialties of medicine1,5,6,17,26. However, no study has evaluated the reporting 
quality of RCTs focusing on efficacy and safety of new oral anticoagulants versus 
warfarin, administered in patients with non valvular atrial fibrillation, for the prevention 
of stroke and systemic embolism.  
 
Atrial fibrillation is the most common arrhythmia in adults27. The estimated numbers of 
men and women with AF worldwide in 2010 were 20.9 million and 12.6 million, 
respectively, with higher incidence and prevalence rates in developed countries27-28. It 
affects more often older people27 and patients with comorbidities such as hypertension, 
heart failure, coronary artery disease (CAD), valvular heart disease, obesity, diabetes 
mellitus, or chronic kidney disease (CKD)29-30. It is independently associated with a two-
fold increased risk of all-cause mortality in women and a 1.5-fold increase in men. It is 
also associated with increased morbidity and hospitalizations due to heart failure or 
stroke. Recent studies show that 20-30% of all strokes are due to atrial fibrillation27-29.  
 
The most popular anticoagulation treatment, so far, for the prevention of stroke in AF 
patients, has been considered warfarin and other vitamin K antagonists, reducing the 
risk of stroke by about two thirds31. However, their use is limited by a narrow therapeutic 
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range, drug and food interactions, required monitoring of INR, and risk of bleeding31. 
Thus, in the last fifteen years, research has been focused on assessing the efficacy and 
safety of new oral anticoagulants against warfarin in AF patients, and a number of large 
multi-centered RCTs have been conducted for this purpose32-35. The majority of 
published results show that there is a number of new drugs that are non-inferior to 
warfarin as far as efficacy (prevention of stroke/systemic embolism/death) and safety 
(major bleeding events) are concerned and thus they could be used instead of vitamin K 
inhibitors in a subgroup of patients with non valvular AF132. This observation has a great 
clinical and scientific impact and is expected to change patients’ management. 
 
However, in order to make such a crucial clinical decision, we should first assess the 
quality of these trials to ensure the validity of their results. This can be accomplished 
only by a high quality and thorough reporting of trial methodology, conduct and data 
analysis by the authors in order all trial information to be available for assessment. 
Consequently, this field merits detailed assessment of the quality of reports of RCTs, not 
only because of the undoubted high prevalence of AF in general population, but also of 
its major clinical complications, that have to be prevented, by means of the appropriate 
treatment based on reliable evidence.   
 
The main objective of this study is to assess the overall reporting quality of RCTs, 
exploring the efficacy and safety of NOACs vs warfarin in patients with AF, based on the 
25-item checklist of the CONSORT statement 2010. 
 
 
 
C. Methods 
Studies Selection and Data Extraction 
Literature was systematically identified by searching PubMed for reports of RCTs 
investigating the efficacy and safety of all NOACs vs warfarin in patients with AF, 
published until 15 August 2016 without any other time limitation, since all RCTs on 
NOACs have been published after 2003, which means that the Consort Statement was 
already published and so there are no confounders. For our search we used as filters the 
"Randomized Controlled Trial" type of article, "English" language, "Humans", and as a 
search criterion the following terms: “(apixaban OR edoxaban OR dabigatran OR 
rivaroxaban) vs warfarin AND atrial fibrillation, (new oral anticoagulants OR oral 
thrombin inhibitors OR oral factor Xa inhibitors)  vs warfarin AND atrial fibrillation,  as 
well as (ximelagatran OR darexaban OR betrixaban OR AZD08327) vs warfarin AND atrial 
fibrillation” in order to cover the whole spectrum of RCTs on new oral anticoagulants in 
AF and not only RCTs on NOACs that are already on market. Trials were eligible if they 
had randomly assigned participants to at least two treatment arms and if they had 
investigated the efficacy and safety of NOACs vs Warfarin in patients with AF. We also 
included all published articles reporting all results of predefined or post hoc secondary 
analysis of the primary clinical trials. We included only published work as a full article. 
Reviews, editorials, letters and short articles were excluded. All references cited in the 
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retrieved articles were also reviewed to identify additional published work not indexed 
by PubMed.  
 
All extracted eligible articles have been assessed for their quality of reporting using the 
revised CONSORT checklist of 2010 (http://www.consort-statement.org)3. Consort 
checklist includes a 25-item-questionaire, regarding the title, summary, introduction, 
methodology, results, discussion and other information of the trial.  12 items are divided 
into two subcategories a and b. In an attempt to determine better internal and external 
validity, one item from the CONSORT checklist, namely 14a: dates defining the periods 
of recruitment and follow up was divided into two sub-items (recruitment and follow-
up). Hence, based on CONSORT items, we developed a 25-item data extraction sheet 
with 11 double items kai 1 triple item. So, the total number of questionnaire items that 
we used to assess the reporting quality of RCT reports were 38. We present the whole 
questionnaire with each item in detail in Table 2. 
 
All items were investigated in terms of whether they were reported and not whether 
they were actually carried out during the trial. The following CONSORT items, regarding 
trial methodology were not mandatory to be reported, if they were not carried out 
during the trial or they were not included in the trial protocol: 3b. Important changes to 
methods after trial commencement with reasons, 6b. Any changes to trial outcomes 
after the trial commenced, with reasons, 7b. When applicable, explanation of any 
interim analyses and stopping guidelines, 11a. If done, who was blinded after 
assignment to interventions and how, 11b. If relevant, description of the similarity of 
interventions, 12b. Methods for additional analyses, such as subgroup analyses and 
adjusted analyses and 14b. Why the trial ended or was stopped. In case they were not 
carried out during the trial, they were coded as not applicable (N/A) (Table 2). In 
addition, items that were partially reported were coded as positive. For example, some 
trials reported item 3a. (Description of trial design (such as parallel, factorial) including 
allocation ratio), only as far as study design was concerned, but they did not clearly 
report the allocation ratio. We coded such reports as positive.  Furthermore, in a large 
number of retrospective and predefined sub-analysis reports of RCTs, most items, 
regarding methodological approaches of the RCT, were not reported in detail, and 
instead, a reference of the study protocol or the primary report of RCT was cited. If these 
items were not reported at all, we coded them as negative. We present the results of all 
such partially or not clearly reported items, in detail, in section D (Τable 2 and 3).  
 
Methodological Evaluation and Statistical Methods 
 
Each extracted article was thoroughly evaluated for every single item of the CONSORT 
checklist. The reported items were coded as positive, the not reported as negative and 
these that were not carried out, as mentioned above, as not applicable. 
In addition, articles were grouped in subgroups, according to whether the results were 
related to the primary analysis of a randomized controlled clinical trial or to predefined 
or retrospective post hoc secondary subgroup analysis and also according to the new 
oral anticoagulant drug that they were referred to.  
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Following this procedure, the extent of adjustment of each article to the total number 
of CONSORT checklist items was also assessed, as well as the frequency of overall articles 
that reported each one of the CONSORT checklist items separately. A comparison was 
made by means of chi-square test both between subgroups of anticoagulant drugs and 
between subgroups of type of result analysis, both in the total CONSORT item adherence 
of each article and in the frequency of articles of each subgroup that reported each 
Consort item.  
 
Furthermore, all Journals, in which eligible for evaluation articles have been published, 
were searched and listed according to the ISI (Institute for Scientific Information) Impact 
Factor (IF) for 2015. Journals were also reviewed for their endorsement to the CONSORT 
statement, which is usually clearly mentioned in Journal’s instructions for authors on 
how to report clinical trials or there is a statement that the Journal adheres to the 
directives of International Committee of Medical Journal Editors that has also endorsed 
the CONSORT Statement 2010.  
  
Finally, articles were grouped, according to whether they had been published in a high 
or low impact Journal, into two subgroups (IF>10 or IF<10) and were evaluated for their 
adherence to CONSORT items. The selection of IF>10 as the cut-off point was arbitrary. 
For the comparison of the two groups regarding the relation between Journal’s IF and 
the grade of CONSORT adherence we used chi-square test. We compared also the 
frequencies of articles of each group that reported some important Consort items to 
investigate if there was a significant difference using chi-square test. 
 
Although all items in the CONSORT checklist are considered important for improvement 
of quality of reports of RCTs, some are more subjective than others to assess potential 
biases. Emphasis was placed on reporting of methodological items such as study design, 
sample size estimation, method of randomization and allocation concealment, 
performed statistical methods, description of baseline data, precision of estimated 
effect size, and reporting of whether the analysis was made by original assigned groups. 
 
All variables are categorical and they are presented as frequency distributions 
(proportions) together with absolute values. The cutoff point for statistical significance 
was set at the two-sided 0.05 level. All statistical analyses were performed with the use 
of SPSS software version 22.  
 
 
D. Results 
 
Eligible studies 
 
A total of 422 potentially eligible references were identified (Fig.1), of which 4 were 
found to be duplicates. The remaining 418 unique citations were screened for eligibility. 
After eligibility screening, 8 citations that were not in English and another 318 citations 
that did not fulfill the inclusion criteria were excluded ( 16 study protocols, 32 studies 
compared NOACs or warfarin with aspirin or heparin in AF patients, 74 articles referred 
to NOACs in venous thromboembolism and orthopedics, 120 pharmacodynamics 
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studies, 46 studies referred to other heart diseases, 15 articles that were not RCTs, such 
as reviews, pooled analysis of many RCTs’ results etc, 15 articles of secondary analysis 
that did not focus on efficacy or safety of NOACs). Consequently, a total of 92 reports 
remained for analysis, requiring complete full-text evaluation. A full list of the 92 reports 
that were retrieved as full-text and included in final analysis is found in section F (32-
126).  
 
 
FIGURE 1. Flow diagram of citations through the retrieval and the screening process.  
 
 
Main results 
 
Among 92 eligible reports32-126, 18 (20%) are reports of RCT primary results (8 RCTs 
phase III and 10 RCTs phase II), 32 (35%) are reports of predefined subgroup analysis of 
RCTs and 42 (45%) are reports of retrospective post hoc secondary analysis of primary 
data of RCTs.  
Furthermore, of 92 reports for assessment, 18 articles are referred to apixaban (20%), 
12 to edoxaban (13%), 22 to dabigatran (24%), 31 to rivaroxaban (34%), 5 to 
References Identified 
in PubMed and cited 
references N=422 
Excluded  N=326 
-16 protocols 
-32 studies compared NOACs or 
warfarin with aspirin or heparin 
-74 studies related with venous 
thromboembolism 
-120 farmakodynamic studies 
- 46 other heart diseases 
-8 no summary/other language 
-15 not RCTs 
- 15 not efficacy/safety studies 
 
References retrieved as full 
text and included in final 
analysis: N=92 
-4 duplicates 
 
Assessed for eligibility   
N=418 
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ximelagatran (5,5%), 2 to AZD0328, 1 to darexaban and 1 to betrixaban. The 9 last 
reports (10%) are referred in the tables below as “other drugs”. 
 
 As for the discrimination of reports according to the impact factor of Journals, 57 (62%) 
articles have been published in high-ranked Journals with IF>10 and 35 (38%) in low-
ranked Journals with IF<10. The total number of Journals in which evaluated articles 
have been published are 25 and 10 of them (40%) are high-ranked with an IF>10. 23 out 
of 25 journals (92%) have endorsed the Consort statement. 
 
In table 1 there are the percentages of CONSORT items, in total, that are reported by 
the total number of articles and by each group of articles according to the study type.  
All trials report >45% of Consort items. 26% (n=24) of the total number of evaluated 
articles report > 70% of Consort items and 10,8% of the studies report<50% of Consort 
items. This result can be interpreted by the following outcomes:  
All RCTs (n=18) report >70% of Consort items, while 50% of them report >80% and 11% 
report >90% of the items. However, < 80% of Consort items are reported in both pre-
specified subgroup and post hoc analysis articles, with the majority of the articles 
reporting between 50 and 70% of Consort items in both groups.  
 
We compared the three groups, as to whether there is a significant difference among 
them, in their compliance to the Consort Statement, using x2 test and found that 
x2=107,3, degrees of freedom (df)=2 with p=0.0001<0,001, which means that there is a 
statistical significant correlation between the type of reported article and the 
compliance with Consort items. Then, we compared “the primary report of RCT group” 
with the group of secondary analysis trials (pre-specified and post hoc together in one 
group) using x2 test in order to define the absolute and relative effect size of this 
correlation. The results are: x2=105 df=1, p=0,00001<0,01 with Odds Ratio (OR) =3,1 and 
95% Confidence Interval (C.I) = (2,4 – 3,8). So, there is a 3-fold greater possibility of 
reporting Consort items in “primary report of RCT” group in comparison with secondary 
analysis group. 
 
 
 
 
Table 1: Percentage of CONSORT items reported by each article grouped by study types 
 [45-50] % 
 
N/ % 
(50-60] % 
 
N/% 
(60- 70] % 
 
N/% 
(70-80] % 
 
N/% 
(80-90]% 
 
N/% 
>90 % 
 
N/% 
Total 
RCT main 
results 
0 0 0 7 (38,8%) 9 (50%) 2(11,1%) 18 
Prespecified 
subgroup 
analysis 
1 (3,1%) 13 (40,6%) 14 (43,7%) 4 (12,5%) 0  0 32 
Post hoc 
analysis 
9 (21,4%) 15 (35,7%) 16 (38,1%) 2(4,7%) 0 0 42 
Total 10 (10,8%) 28 (30,4%) 30 (32,6%) 13 (14,1%) 9 (9,7%) 2 (2,1%) 92 
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In table 2, all items of Consort checklist 2010 are presented in detail with our 
modification in item 14a. Absolute values and frequencies of the total number of 
evaluated articles (n=92), that report each one of the checklist items, are also reported. 
For each Consort item, we present the absolute value(n) and frequency of articles that 
report it, the absolute value(n) and frequency of articles that do not report it and the 
number of articles in which this item is not applicable. In each reported item, the 
numbers of trials that report it partially are also presented. In column “not reported”, 
we present in detail the number and frequency of articles that cite a reference of the 
primary RCT instead of clearly report several items of the checklist. 
 
If we look thoroughly at every item of the checklist below the following observations 
have to be made: 
 14 out of 38 checklist items are reported by less than 50% of evaluated studies. 
 Only 17 (18%) trials are reported as randomized in the title(1a) 
 Items 1b, 2a, 2b regarding a structured summary, scientific background and 
rationale and specific objectives of the study are reported by almost all studies, 
namely 100%, 99%, 99% respectively 
 The study design is reported by 82% of the trials (n=75), of which 65% (n=49) of 
articles do not report the allocation ratio 
 The eligibility criteria are reported in 70%(n=67) of the studies, while settings 
and locations of the trial in about 50% (n=45). 
 Items 5 and 6a regarding the description of interventions for each group and the 
primary and secondary outcomes are reported by a large proportion of studies 
>90%. However, the estimation of sample size(7a) is reported only by 20% of 
trials, while 72 articles (secondary analysis) report it via a reference to the 
protocol or primary RCT article. 
 As for the randomization is concerned, there is low frequency of reporting. The 
method used to generate the random allocation sequence(8a) is reported by 
only 21% of eligible articles(n=19), type of randomization(8b) by 17% of articles 
(n=16), of which 7 articles (43%) report it only partially without any further 
explanation of the restrictions such as the block size. The allocation concealment 
mechanism sequence is reported only by 11%(n=10) of the trials, while the 
implementation (10) by only 3%(n=3). 
 As for the blinding, 90 out of 92 trials were blinded, but only 50 trials report it 
(54%), of which 82% (n=41) report it partially (it is referred that the trial is 
double-blinded without any explanations of how blinding was implemented). In 
addition, only 13%(n=12) of the trials describe the similarity of interventions. 
 Statistical methods used to compare groups for primary and secondary 
outcomes are reported by 99% of the articles and methods for ancillary analysis 
by 87%(n=80) while in 8(9%) studies there was no further sub-analysis (n/a) to 
be described. 
 In results, only 33% of the studies(n=30) present a flow diagram(13a) of which 5 
studies present a diagram of the population included in the secondary analysis. 
27 studies (29%) report the loses and exclusions after randomization(13b) (2 of 
them do not report the reasons). 
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 About 40% of the trials, describe dates of recruitment and follow up (14a1/14a2). 
A proportion of trials do not report the dates, but the duration of recruitment 
and follow up in months. 
 99% of the trials, fully report items 15, 17a and 17b, regarding the presentation 
of tables with demographic characteristics (15), results for each group, with the 
estimated effect size and its precision for predefined outcomes and for binary 
outcomes absolute and relative effect sizes (17a and 17b). For post hoc analysis 
trials, results are presented with the estimated effect size and its precision for 
outcomes that were defined afterwards. Nearly 90% of the studies, report results 
of secondary subgroup analysis, defining if it is pre-specified or exploratory. 
 Item 16, which is really important for the clinician, regarding the number of 
participants (denominator) included in each analysis and whether the analysis 
was by original assigned groups is reported by all trials 100%, but 5 RCTs report 
that the analysis was not performed by original assigned groups and in 74 articles 
the analysis was performed in subgroups. These details are reported in order the 
reader to Know which trial population was included in the analysis. 
 As for the harms of the trial, item 19, only 30% of the trials fully report all of 
them.  
 In discussion part, 90% of articles report trial limitations, while nearly all articles 
clarify the external validity of the trial (99%), and all reports interpret the results 
taking into consideration harms and costs and other trials’ findings. 
 Finally, all reports name the funder and its role, while 61% report the trial 
registration number and 72% cite a reference of the trial protocol. 
 We can conclude, that most important methodological items (3,5,6a,12a,12b) 
and items related with the presentation of results (15,16,17,18) are well 
reported by all articles. 
 
 
In table 3, absolute values and frequencies of evaluated articles of each study group for 
each reported Consort item are thoroughly presented, together with p-values, indicating 
the differences in reporting of each Consort item among the three groups, estimated 
with x2 test.   
 
In every group, absolute values and frequencies of articles that partially report or do not 
report but cite a reference of an item are also referred.  
Items 3a, 5, 6a, 15,16,17a,17b which are of great importance are reported by 100% of 
RCTs, while items 7a and 12a, 13a and 13b are presented by 94% (n=17) of RCTs. So, the 
most important items for the evaluation of the quality of a randomized clinical trial are 
reported in almost all RCTs. Items 8a, 8b and 9 regarding randomization are reported by 
about 50% of RCTs. 
 
In the other two groups of evaluated articles, that report secondary analysis outcomes, 
compliance with Consort items is lower with statistical significant differences (p<0,05) 
among the three groups for the majority of items:1a, 3a, 3b, 4a, 4b, 6a, 7a, 8a, 8b, 9,10, 
11a,11b, 13a, 13b, 14a1, 14a2, 19, 20, 24. However, results are fully reported (items: 15, 
16, 17a,17b,18) by all secondary analysis articles (100%) without statistical significant 
differences between the two groups and the RCT group.  
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Table 2: Items of CONSORT Statement 2010. Absolute values and frequencies of articles reporting each single item of 
the checklist  
Section/Topic Item Checklist item Reported  
 
Freq (N) 
Not 
Reported 
Freq (N) 
Ν/Α 
 
Freq(N) 
                                                   Total studies assessed: n=92 
Title and abstract 
 1a Identification as a randomised trial in 
the title 
0.18 (17) 0.82 (75) 0 
 1b Structured summary of trial design, 
methods, results, and conclusions  
1.0 (92) 0 0 
Introduction 
Background and 
objectives 
2a Scientific background and explanation 
of rationale 
0.99 (91) 0.01 (1) 0 
 2b Specific objectives or hypotheses 0.99 (91) 0.01 (1) 0 
Methods 
Trial design 3a Description of trial design (such as 
parallel, factorial) including allocation 
ratio 
Total: 0.82(75) Reference: 
0.18 (17) 
0 
Partially: 0.65 
(49) 
 3b Important changes to methods after 
trial commencement (such as eligibility 
criteria), with reasons 
0.04 (4) Reference: 
0.28 (26) 
0.67 
(62) 
Participants 4a Eligibility criteria for participants 0.7 (64) Total: 0.3 (28) 0 
Reference: 
0.96 (27) 
 4b Settings and locations where the data 
were collected 
0.49 (45) 0.51 (47) 0 
Interventions 5 The interventions for each group with 
sufficient details to allow replication, 
including how and when they were 
actually administered 
0.92 (85) 0.08 (7) 0 
Outcomes 6a Completely defined pre-specified 
primary and secondary outcome 
measures, including how and when they 
were assessed 
0.90 (83) 0.10 (9) 0 
 6b Any changes to trial outcomes after the 
trial commenced, with reasons 
0 0 1.0 (92) 
Sample size 7a How sample size was determined 0.21 (19) Total: 0.79 
(73) 
0 
Reference: 
0.99 (72) 
 7b When applicable, explanation of any 
interim analyses and stopping 
guidelines 
0.05 (6) Reference: 
0.5 (45) 
0.45 
(41) 
Randomisation: 
 Sequence 
generation 
8a Method used to generate the random 
allocation sequence 
0.21 (19) Total: 0.79 
(73) 
0 
Reference: 
0.59 (43) 
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 8b Type of randomisation; details of any 
restriction (such as blocking and block 
size) 
Total: 0.17 (16) Total: 0.83(76) 0 
Partially: 0.43 
(7) 
Reference: 
0.28 (21) 
Allocation 
concealment 
mechanism 
9 Mechanism used to implement the 
random allocation sequence (such as 
sequentially numbered containers), 
describing any steps taken to conceal 
the sequence until interventions were 
assigned 
0.11 (10) Total: 0.89 
(82) 
0 
Reference: 
0.02 (2) 
 
Implementation 
10 Who generated the random allocation 
sequence, who enrolled participants, 
and who assigned participants to 
interventions 
0.03 (3) 0.97 (89) 0 
Blinding 11a If done, who was blinded after 
assignment to interventions (for 
example, participants, care providers, 
those assessing outcomes) and how 
Total: 
0.54 (50) 
Total: 
0.43 (40) 
0.03 (2) 
Partially: 0.82 
(41) 
Reference: 
0.98 (39) 
 11b If relevant, description of the similarity 
of interventions 
0.13 (12) Total: 0.85 
(78) 
0.02 (2) 
Reference:  
0.88 (69) 
Statistical 
methods 
12a Statistical methods used to compare 
groups for primary and secondary 
outcomes 
0.99 (91) 0.01 (1) 0 
 12b Methods for additional analyses, such 
as subgroup analyses and adjusted 
analyses 
0.87 (80) 0.04 (4) 0.09 (8) 
Results 
Participant flow 
(a diagram is 
strongly 
recommended) 
13a For each group, the numbers of 
participants who were randomly 
assigned, received intended treatment, 
and were analysed for the primary 
outcome 
Total: 0.33 (30) Total: 0.67 
(62) 
0 
Substudy 
population: 
0.17 (5) 
Reference:  
0.52 (32) 
 13b For each group, losses and exclusions 
after randomisation, together with 
reasons 
Total: 0.29 (27) 0.71 (65) 0 
Partially: 0.07 
(2) 
Substudy 
population: 
0.19 (5) 
Recruitment 14a1 Dates defining the periods of 
recruitment  
Total: 0.39 (36) 0.61 (56) 0 
Months: 0.08 
(3) 
 14a2 Dates defining the periods of follow-up Total: 0.41 (38) 0.59 (54) 0 
Months: 0.66 
(25) 
 14b Why the trial ended or was stopped 0 0 1.0 (92) 
Baseline data 15 A table showing baseline demographic 
and clinical characteristics for each 
group 
0.99 (91) 0.01 (1) 0 
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Table 3: Absolute values and frequencies of evaluated articles reporting each single item of checklist among the 
three study groups and significance estimate (p-value) of difference. 
Item   Total 
  n=92 
 
RCT primary 
reports 
  n=18 
Predefined sub-
analysis 
n=32      
Post hoc 
analysis  
n=42 
P value 
 Freq (N) Freq (N)           Freq (N) Freq (N)  
1a 0.18 (17) 0.39 (7) 0.18 (6) 0.01 (4) 0,027 
1b 1.0 (92) 1.0 (18) 1.0 (32) 1.0 (42) 1 
2a 0.99 (91) 1.0 (18) 1.0 (32) 0.98 (41) 0,548 
Numbers 
analysed 
16 For each group, number of participants 
(denominator) included in each analysis 
and whether the analysis was by 
original assigned groups 
Total: 1.0 (92) 0 0 
Other analysis  
RCT: 0.05 (5) 
Subgroup: 0.8 
(74) 
Outcomes and 
estimation 
17a For each primary and secondary 
outcome, results for each group, and 
the estimated effect size and its 
precision (such as 95% confidence 
interval) 
0.99 (91) 0.01 (1) 0 
 17b For binary outcomes, presentation of 
both absolute and relative effect sizes is 
recommended 
0.99 (91) 0.01 (1) 0 
Ancillary analyses 18 Results of any other analyses 
performed, including subgroup analyses 
and adjusted analyses, distinguishing 
pre-specified from exploratory 
0.89 (82) 0.01 (1) 0.1 (9) 
Harms 19 All important harms or unintended 
effects in each group  
0.3 (27) 0.7 (65) 0 
Discussion 
     
Limitations  20 Trial limitations, addressing sources of 
potential bias, imprecision, and, if 
relevant, multiplicity of analyses 
0.90 (83) 0.1 (9) 0 
Generalisability  21 Generalisability (external validity, 
applicability) of the trial findings 
0.99 (91) 0.01 (1) 0 
Interpretation  22 Interpretation consistent with results, 
balancing benefits and harms, and 
considering other relevant evidence 
1.0 (92) 0 0 
Other information 
Registration 23 Registration number and name of trial 
registry 
0.61 (56) 0.39 (36) 0 
Protocol 24 Where the full trial protocol can be 
accessed, if available 
0.72 (66) 0.28 (26) 0 
Funding 25 Sources of funding and other support 
(such as supply of drugs), role of 
funders 
1.0 (92) 0 0 
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2b 0.99 (91) 1.0 (18) 0.97 (31) 1.0 (42) 0,388 
3a 0.82 (75) Total: 1.0 (18) Total: 0.84(27) 0.71 (30) 
0,029 Partially: 
0.39 (7) 
Partially: 0.47 (15) 
3b 0.16 (4/24) 1.0 (3/3) 0.07 (1/14) 0 0,0001 
4a 0.7 (64) 1.0 (18) 0.78 (25) 0.5 (21) 0,0001 
4b 0.49 (45) 0.89 (16) 0.47 (15) 0.33 (14) 0,0001 
5 0.92 (85) 1.0 (18) 0.94 (30) 0.88 (37) 0,263 
6a 0.90 (83) 1.0 (18) 0.97 (31) 0.81 (34) 0,022 
6b N/A N/A N/A N/A 1 
7a 0.21 (19) 0.94 (17) 0.03 (1) 0.02 (1) 0,0001 
7b 0.12 (6/51) 1.0 (5/5) 0.04 (1/23) 0 0,0001 
8a 0.21(19) 0.5 (9) 0.22(7) 0.07 (3) 0,0001 
8b 0.17 (16) 0.57 (10) Total: 0.16 (5) 0.02 (1) 0,001 
Partially: 0.8 (4) 
9 0.11 (10) 0.45 (8) 0.03 (1) 0.02 (1)  0,001 
10 0.03 (3) 0.27 (3) 0 1.0 (42) 0,002 
11a 0.56 (50/90) Total:  
0.83 (15) 
Total: 
0.47 (15) 
Total: 0.48 (20) 0,003 
Partially:  
0.8 (12) 
Partially: 
0.67 (10) 
Partially: 
0.86 (19) 
11b 0.13 (12/90) 0.33 (6) 0.16 (5) 0.02 (1) 0,002 
12a 0.99 (91) 0.94 (17) 1.0 (32) 1.0 (42) 0,125 
12b 0.95 (80/84) 0.6 (6/10) 1.0 (32) 1.0 (42) 0,0001 
13a 0.33 (30) 0.94 (17) 0.06 (2) 0.26 (11) 0,0001 
13b 0.29 (27) Total: 0.94 (17) 0.03 (1) 0.21 (9) 0,0001 
Partially: 
0.12 (2) 
14a1 0.39 (36) Total: 0.78 (14) 0.38 (12) 0.24 (10) 0,0001 
Months: 0.14 (2) 
14a2 0.41 (38) Total: 0.67 (12) Total: 0.38 (12) Total: 0.3 (14) 0,048 
Months: 0.58 (7) Months: 0.58 (7) Months: 0.78 
(11) 
14b N/A  N/A N/A N/A 1 
15 0.99 (91) 1.0 (18) 0.97 (31) 1.0 (42) 0,388 
16 1.0 (92) Total: 1.0 (18) 1.0 (32) 1.0 (42) 1 
Not ITT: 0.28 (5) 
17a 0.99 (91) 1.0 (18) 1.0 (32) 0.98 (41) 0,548 
17b 0.99 (91) 1.0 (18) 1.0 (32) 0.98 (41) 0,548 
18 0.98 (82/84) 0.8 (8/10) 1.0 (32) 1.0 (42) 0,001 
19 0.3 (27) 1.0 (18) 0.16 (5) 0.10 (4) 0,0001 
20 0.90 (83) 0.67 (12) 0.94 (30) 0.98 (41) 0,001 
21 0.99 (91) 1.0 (18) 1.0 (32) 0.98 (41) 0,548 
22 1.0 (92) 1.0 (18) 1.0 (32) 1.0 (42) 1 
23 0.61 (56) 0.67 (12) 0.62 (20) 0.57 (24) 0,765 
24 0.72 (66) 0.5(9) 0.84 (27) 0.72 (30) 0,035 
25 1.0 (92) 1.0 (18) 1.0 (32) 1.0 (42) 1 
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In table 4, we present the percentages of CONSORT items, in total, that are reported by 
the 5 groups of articles, according to the new oral anticoagulant drug.  
Apixaban trials report<80% of Consort items. 44,4% (n=8) report about 50-60% of the 
items, 33,3%(n=6) report 70-80% of the items, 16,6%(n=3) report 60-70% of the items. 
1 trial (5,5%) reports<50% of the Consort items.  
Edoxaban trials report 50-90% of the Consort items, with 50%(n=6) of the trials reporting 
50-60% of the items and 16,6%(n=2) of the trials reporting 60-70%, 70-80% and 80-90%, 
respectively. 
Dabigatran trials report <90% of Consort items. 86,4%(n=19) of the studies report <70% 
of the items, 9%(n=2) report 70-80% and 4,5% (n=1) report 80-90% of Consort items.  
Rivaroxaban trials report <90% of Consort items. Nearly half of the trials, about 48,3% 
(n=15) report 60-70% of Consort items, 6,4%(n=2) report 70-80% and 9,3%(n=3) report 
80-90% of the items. In addition, 3,2%(n=1) report 40-50% of the items, 32,2%(n=10) 
report 50-60%. 
“Other drug” trials, report >50% of consort items and 55,5%(n=5) of them report>80% 
of the items. 
In addition, we compared the 5 drug subgroups, as to whether there is a significant 
difference among them, regarding their compliance to the Consort Statement, using x2 
test and found that x2=32,2 for df=4 with p=0.0001<0,001, which means that there is a 
statistical significant correlation between articles referred to a specific NOAC and their 
compliance with the Consort items. 
 
Table 4: Percentage of CONSORT items reported by each article grouped by type of NOAC  
 [45-50]% 
 
N/% 
(50-60] % 
 
N/% 
(60- 70] % 
 
N/% 
(70-80] % 
 
N/% 
(80-90]% 
 
N/% 
>90 % 
 
N/% 
Total 
Apixaban 1 (5,5%) 8 (44,4%) 3 (16,6%) 6 (33,3%) 0 0 18 
Edoxaban 0 6 (50%) 2 (16,6%) 2 (16,6%) 2 (16,6%) 0 12 
Dabigatran 8 
(36,3%) 
3 (13,6%) 8 (36,3%) 2 (9%) 1 (4,5%) 0 22 
Rivaroxaba
n 
1 (3,2%) 10 
(32,2%) 
15(48,3%) 2 (6,4%) 3 (9,6%) 0 31 
Other drug 0 1 (1,1%) 2 (22,2%) 1 (1,1%) 3 (33,3%) 2(22,2%) 9 
Total 10 
(10,8%) 
28 
(30,4%) 
30 (32,6%) 13 (14,1%) 9 (9,7%) 2 (2,1%) 92 
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In table 5, we present frequencies and absolute values of articles reporting each single 
item of checklist among the five drug subgroups and the significance estimate (p-value) 
of difference.  
Statistical significant difference(p<0,05) among drug subgroups is identified in items 1a, 
3a, 4a, 7a, 9, 10, 11a, 13a, 13b, 19, 20. Item 1a, about reporting of randomization in the 
title, is reported most by edoxaban group (50%) and least by apixaban and rivaroxaban 
group (3% and 5%). Item 3a about study design and allocation ratio is reported most by 
edoxaban (100%) and rivaroxaban groups (97%) and least by dabigatran group (50%). 
Item 7a, about sample size estimation, is reported by 67% of “other drug” group and 
10% of apixaban group. Item 13a, about patients’ flow diagram is reported most by 
“other drug” group (78%) and least by dabigatran group (18%). Similar are the results 
for 13b item. In items 5, 6a, 12a, 15,16,17a, 17b, 18, which are important for the 
evaluation of reporting quality of a trial, there is no significant difference among drug 
subgroups and the percentages are high (90-100%) in every group, except for the 
dabigatran group in which about 80% of the articles report items 5 and 6a.  
In table 6, we present the percentage of CONSORT items reported by two groups of 
articles, those published in high-ranked journals with IF>10 and those published in 
Journals with IF<10.  
As we can see from the results in table 6, in “IF>10” group, 7% of articles report <50% of 
the Consort items, 66,5%(n=38) of articles report 50-70% of the items, 14%(n=8) of them 
report 70-80% of the items and only 12,2% (n=7) report>80% of Consort items. For the 
other group of articles, the results are similar to the “IF>10” group. 17,1%(n=6) of the 
articles report<50% of Consort items, 57%(n=20) report 50-70% of the items, 
14,2%(n=5) of them report 70-80% of the items and only 11,4%(n=4) report>80% of 
Consort items. We compared the two groups using x2 test, in order to examine if there 
is significant correlation between the impact factor of journals and the compliance with 
the Consort checklist items. The results are: x2=0,34 for df=1, p=0,55>0,05 and OR=1,05 
with 95% C.I = (0,9 – 1,2). So, we conclude that there is no significant difference between 
the two groups in their compliance to the Consort items, which means that both articles 
published in high-ranked journals and articles published in lower impact factor Journals 
had the same compliance to the Consort Statement.  
Finally, in table 7, we examined if there is a difference between articles published in high 
and low ranked journals regarding the reporting of several important checklist items. 
There is no statistical significant difference between the groups regarding all important 
items for the evaluation of a trials’ quality. Only for two items, (23 and 24) related with 
the registration number of the trial and the citation of the trial’s protocol, there is 
significant difference between the groups.  
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Table 5:  Absolute values and frequencies of articles reporting each single checklist item among the five drug 
subgroups and significance estimate (p-value) of difference. 
Item   Total 
  n=92 
Freq (N) 
Apixaban 
n=18 
Freq (N) 
Edoxaban 
n=12 
Freq (N) 
Dabigatran 
n=22 
Freq (N) 
Rivaroxaban 
n=31 
Freq (N) 
Other 
n=9 
Freq (N) 
P value 
1a 0.18 (17) 0.05(1) 0.5 (6) 0.23 (5) 0.03 (1) 0.44 (4) 0,001 
1b 1.0 (92) 1.0 (18) 1.0 (12) 1.0 (22) 1.0 (31) 1.0 (9) 1 
2a 0.99 (91) 1.0 (18) 1.0 (12) 0.95 (21) 1.0 (31) 1.0 (9) 0,522 
2b 0.99 (91) 1.0 (18) 1.0 (12) 0.95 (21) 1.0 (31) 1.0 (9) 0,522 
3a 0.82 (75) 0.78(14) 1.0 (12) 0.5 (11) 0.97 (30) 0.89 (8) 0,001 
3b 0.16 (4/24) Ν/Α 0.13 (1/8) 0,16 (3/18) Ν/Α Ν/Α 0,815 
4a 0.7 (64) 0.78(14) 0.92 (11) 0.5 (11) 0.61 (19) 1.0 (9) 0,016 
4b 0.49 (45) 0.55(10) 0.25 (3) 0.54 (12) 0.37 (13) 0.78 (7) 0,139 
5 0.92 (85) 0.94 (17) 0.92 (11) 0.81 (18) 0.97 (30) 1.0 (9) 0,267 
6a 0.90 (83) 0.89 (16) 0.92 (11) 0.81 (18) 0.93 (29) 1.0 (9) 0,527 
6b Ν/Α Ν/Α Ν/Α Ν/Α Ν/Α Ν/Α 1 
7a 0.21 (19) 0.11(2) 0.25 (3) 0.13 (3) 0.16 (5) 0.67 (6) 0,008 
7b 0.12 (6/51) 0.06 (1/17) 0.11 (1/9) 0.1 (2/20) N/A 2/5 0,215 
8a 0.21(19) 0.22 (4) 0.33 (4) 0.18 (4) 0.13 (4) 0.33 (3) 0,508 
8b 0.17 (16) 0.27 (5) 0.16 (2) 0.09 (2) 0.09 (3) 0.44 (4) 0,082 
9 0.11 (10) 0.05(1) 0.16 (2) 0.045 (1) 0.03 (1) 0.55 (5) 0,001 
10 0.03 (3) 0 0.08 (1) 0 0 0.22 (2) 0,009 
11a 0.56 (50/90) 0.55(10) 0.42( 5) 0.31 (7) 0.72 (21/29) 0.78 (7) 0,026 
11b 0.13 (12/90) 0.05(1) 0.16 (2) 0.18 (4) 0.14 (4/29) 0.11 (1) 0,818 
12a 0.99 (91) 0.94 (17) 1.0 (12) 1.0 (22) 1.0 (31) 1.0 (9) 0,385 
12b 0.95 (80/84) 0.94 (16/17) 1.0 (11/11) 0.90 (19/21) 0.97 (29/30) 1.0(5/5) 0,730 
13a 0.33 (30) 0.33 (6) 0.33 (4) 0.18 (4) 0.3 (9) 0.78 (7) 0,031 
13b 0.29 (27) 0.28 (5) 0.42( 5) 0.13 (3) 0.25 (8) 0.67 (6) 0,045 
14a1 0.39 (36) 0.33 (6) 0.42( 5) 0.36 (8) 0.32 (10) 0.78 (7) 0,158 
14a2 0.41 (38) 0.5 (9) 0.42( 5) 0.36 (8) 0.32 (10) 0.67 (6) 0,377 
14b N/A N/A N/A N/A N/A N/A 1 
15 0.99 (91) 1.0 (18) 0.92 (11) 1.0 (22) 1.0 (31) 1.0 (9) 0,150 
16 1.0 (92) 1.0 (18) 1.0 (12) 1.0 (22) 1.0 (31) 1.0 (9) 1 
17a 0.99 (91) 0.94 (17) 1.0 (12) 1.0 (22) 1.0 (31) 1.0 (9) 0,385 
17b 0.99 (91) 0.94 (17) 1.0 (12) 1.0 (22) 1.0 (31) 1.0 (9) 0,385 
18 0.98 (82/84) 0.94 (16/17) 0.92 (11) 1.0 (20/20) 1.0 (30/30) 1.0(5/5) 0,397 
19 0.3 (27) 0.11 (2) 0.33 (4) 0.28 (6) 0.25 (8) 0.78 (7) 0,01 
20 0.90 (83) 0.94 (17) 0.83 (10) 0.91 (20) 0.93 (29) 0.78 (7) 0,01 
21 0.99 (91) 1.0 (18) 1.0 (12) 1.0 (22) 0.97 (30) 0.78 (7) 0,560 
22 1.0 (92) 1.0 (18) 1.0 (12) 1.0 (22) 1.0 (31) 1.0 (9) 1 
23 0.61 (56) 0.67(12) 0.75 (9) 0.68 (15) 0.54 (17) 0.33 (3) 0,278 
24 0.72 (66) 0.83 (15) 0.58 (7) 0.72 (16) 0.77 (24) 0.44 (4) 0,194 
25 1.0 (92) 1.0 (18) 1.0 (12) 1.0 (22) 1.0 (31) 1.0 (9) 1 
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Table 6: Percentage of CONSORT items reported by each article grouped by Journals’ Impact Factor 
 [40-50] % 
 
N/% 
(50-60] % 
 
N/% 
(60- 70] % 
 
N/% 
(70-80] % 
 
N/% 
>80% 
 
N/% 
Total 
IF>10 4(7%) 18(31,5%) 20(35%) 8(14%) 7(12,2%) 57  
IF<10 6(17,1%) 10(28,5%) 10(28,5%) 5(14,2%) 4(11,4%) 35 
Total 10 (10,8%) 28 (30,4%) 30 (32,6%) 13 (14,1%) 11(12%) 92 
Table 7: Absolute values and frequencies of articles reporting several checklist items in high and low 
ranked journals and estimated precision 
Item   Total 
  n=92 
Freq (N) 
IF>10 
n=57 
Freq (N) 
IF<10 
n=35 
Freq (N) 
P value 
1a 0.18 (17) 0.2 (11) 0.17 (6) 0,796 
2b 0.99 (91) 0.98 (56) 1.0 (35) 0,431 
3a 0.82 (75) 0.84(48) 0.77 (27) 0,396 
5 0.92 (85) 0.93 (53) 0.91 (32) 0,785 
6a 0.90 (83) 0.89 (51) 0.91 (32) 0,759 
7a 0.21 (19) 0.17(10) 0.26 (9) 0,347 
8a 0.21(19) 0.26 (15) 0.11 (4) 0,087 
8b 0.17 (16) 0.21 (12) 0.11 (4) 0,237 
11a 0.56 (50/90) 0.52(29) 0.6(21) 0,498 
12a 0.99 (91) 1.0 (57) 0.97 (34) 0,199 
13a 0.33 (30) 0.28 (16) 0.4 (14) 0,236 
15 0.99 (91) 0.98 (56) 1.0 (35) 0,431 
16 1.0 (92) 1.0 (57) 1.0 (35) 1 
17a 0.99 (91) 0.98 (56) 1.0 (35) 0,431 
17b 0.99 (91) 0.98 (56) 1.0 (35) 0,431 
18 0.98 (82/84) 0.98 (53/54) 0.96 (29/30) 0,670 
20 0.90 (83) 0.93 (53) 0.86 (30) 0,255 
23 0.61 (56) 0.72(41) 0.42 (15) 0,006 
24 0.72 (66) 0.82 (47) 0.54 (19) 0,004 
25 1.0 (92) 1.0 (57) 1.0 (35) 1 
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E. Conclusion 
 
Taking into consideration, all findings of our analysis presented in this study we can 
conclude the following: 
Since, all evaluated trials have been conducted and reported by cooperating groups of 
scientists and 92% have been published in peer reviewed journals that have endorsed 
the Consort statement, we would expect them to be of high reporting quality. However, 
only 26% (n=24) of the total number of evaluated articles reported >70% of the Consort 
items.  
This remark was not valid for the “primary report of RCT” group, in which all trials(n=18) 
reported >70% of the Consort items, while 61% of them reported >80% and 11% 
reported >90% of the items, which depicted a quite good and satisfactory compliance of 
RCTs to the Consort statement.  
 
On the other hand, <80% of Consort items were reported in both pre-specified subgroup 
and post hoc analysis articles, with the majority of the articles reporting between 50 and 
70% of Consort items in both groups. Consequently, we found a statistical significant 
difference among the three groups.  
 
As for the checklist items separately, 14 out of 38 items were reported by less than 50% 
of evaluated studies. The most important items for the evaluation of the quality of a 
randomized clinical trial (3a,5,6a,12a,12b,13a,15,16,17a,17b,18) are reported in almost 
all RCTs. The randomization items, though, were not reported sufficiently by any group 
of articles. The same comment has to be made for items 1a, 3a,11a, 11b, 14a especially 
for secondary analysis articles.  
 
As far as drug subgroups are concerned, the best compliance with Consort items was 
identified in “other drugs” subgroup with 55,5% of the articles reporting>80% of the 
items, while the worst compliance was observed in apixaban and dabigatran group with 
about 50% of the articles reporting < 60% of the items. This difference can be explained 
by the fact that in other drug group 6 out of 9 reports are primary RCT reports, while in 
apixaban and dabigatran group there are only 2 out of 18 and 3 out of 22 primary RCT 
reports, respectively. The difference among drug groups was statistically significant. 
Significant differences were detected also in several items, such as 1a, 3a, 4b, 7a, 13a, 
among the groups, but in items of clinical importance (12a, 15, 16, 17) all groups had 
similar reporting frequencies. 
 
Finally, no significant correlation was found between the impact factor of journals and 
compliance with the Consort items.  
 
This systematic analysis of the reporting quality of randomized clinical trials, exploring 
the efficacy and safety of NOACs vs warfarin in patients with atrial fibrillation, is subject 
to several important limitations. First of all, 80% (n=74) of articles included in our 
analysis, presented results of secondary analysis of RCT data and thus, they could be 
considered as a confounding factor or effect modifier for the not so satisfactory results, 
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regarding the low compliance of the total number of trials with the Consort items.  This 
hypothesis is confirmed by the high reporting quality of primary reports of RCTs (>70% 
compliance). Furthermore, we searched for literature only in pubmed and in English 
language, which means that a number of potentially relevant to the topic RCTs might 
have not been included in the analysis. Finally, our search was limited in RCTs that 
compared a NOAC with warfarin in terms of efficacy and safety and was not expanded 
in RCTs regarding every anticoagulant and antiplatelet therapy in patients with AF. This 
limitation leaded to a small number of RCTs and a disproportionate number of 
secondary analysis studies. 
 
To sum up, it should be noted that the primary reports of RCTs complied with a 
satisfactory percentage of CONSORT items. Most information given, about the 
methodology and results of RCTs, was clear enough to enable readers to have an 
objective aspect of the quality of these trials and as a consequence, to judge the 
optimistic results for the use of NOACs in patients with AF unbiased. Thus, we could 
assume, based on our analysis and the results from two meta-analysis127-128, that phase 
III RCTs conducted so far about NOACs (apixaban, dabigatran, rivaroxaban, edoxaban) in 
AF patients are sufficiently reported and conducted and these new drugs could be 
administered with safety to a proportion of AF patients with specific characteristics, in 
order to prevent the unwilling complications of AF efficiently. However, significant 
efforts should be made by authors and journals, for a further enhancement of 
compliance with more than 95% of the CONSORT items, both for the RCT primary 
reports and especially for the secondary analysis reports (in order to achieve an 
excellent reporting), so as to enable cardiologists and other physicians to have a more 
clear and precise picture of all aspects ( study design, methodology, analysis) of RCTs in 
the field of NOACs and thus to assess the quality of the studies more accurately and 
come to unbiased estimates of treatment effects useful in every day patients’ care.  
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